openPR Logo
Press release

Spotlight on Key Sessions at Ophthalmic Drugs this November

10-26-2017 12:58 PM CET | Health & Medicine

Press release from: SMi Group

Spotlight on Key Sessions at Ophthalmic Drugs this November

Featuring an exceptional line-up of keynote speakers from industry leading organisations, Europe's leading conference on Ophthalmic Drugs arrives at the perfect time to discuss the latest approaches in key areas such as ocular diseases, drug delivery, pre-clinical and clinical trials, computer technologies and therapies for diabetic macular oedema. www.ophthalmicdrugs.com/opr

Agenda highlights will include a spotlight on dry eyes, therapies for glaucoma and emerging computer technologies to drug development in ophthalmology.

Spotlight Summary on Sessions:

[OPENING ADDRESS] - Novel LFA-1 Antagonist for treatment of Dry Eye Disease – Results from 5 adequate and well controlled trials of Lifitegrast

- Challenges in drug development for Dry Eye disease.
- Development Rationale behind lifitegrast.
- Clinical results from four 12-week efficacy and safety studies and one long term (1-year) safety study.

Amir's talk will discuss the novel approaches to the treatment of ocular diseases, based on the development of lifitegrast, and clinical results from short and long term safety studies. Attendees can benefit and be inspired, as Amir will also provide rationale behind the development of lifitegrast.

Amir Shojaei, Vice President Therapeutic Area Head, Ophthalmology, Shire

[PANEL DISCUSSION] - Applications of emerging computer technologies to drug development

This exclusive Panel Discussion being chaired by Almira Chabi, Senior Director from Santen Inc with panellists from Roche and PharmaMedic, will be discussing:

- The applications of emerging computer technologies to drug development.
- Applications of blockchain in pharma and drug development.
- The changing regulatory landscape in the context of emerging technologies in ophthalmology.

Panellists:
Almira Chabi, Senior Director, Santen Inc
Francis Kendall, Technology Evaluation and Integration Leader Strategic Innovation, Roche
Malcolm Barratt-Johnson, Managing Director, PharmaMedic Consultancy Ltd

Novel Prostaglandins, Conjugate Products and MIGS for Glaucoma Treatment
- Omidenepag Isopropyl: a novel agonist of prostaglandin EP2 receptors to lower IOP.
- The use of conjugate drugs and combination products.
- InnFocus Microshunt MIGS Device for robust IOP reduction.

Naj Sharif, Executive Director in R&D, Head, Global Alliances & External Research, Santen Inc

Here from an exceptional speaker line-up, including:

- Mitchell de Long, Vice President, Chemistry, Aerie Pharmaceuticals
- Sérgio Leal, Ophthalmologist Director, Global Clinical Leader, Bayer
- Victor Chong, Global Head of Ophthalmology, Boehringer Ingelheim
- Tomas Navratil, Senior Vice President, Development, Envisia Therapeutics
- Aniz Girach, Chief Medical Officer, NightstaRx
- Bernhard Gunther, Co-Founder, Chief Innovation Officer, Novaliq GmbH

Further information is available at: www.ophthalmicdrugs.com/opr

For those looking to attend there is currently a £100 early-bird saving by October 31st

SMi Presents the Launch of…
Ophthalmic Drugs
Date: 28th – 29th November 2017
Location: Kensington, London
Website: www.ophthalmicdrugs.com/opr

Sponsored by: Leica Microsystems | Experimentica

---end---

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

1 Westminster Bridge Rd, London SE1 7XW

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Spotlight on Key Sessions at Ophthalmic Drugs this November here

News-ID: 787960 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for Ophthalmic

Ophthalmic Trial Frames Market Depth Survey Report 2019| Topcon, Luneau, Takagi …
Ophthalmic trial frames are adjustable frames that are used to hold lenses during refraction test and during retinoscopy test of the eye. Ophthalmic trial frames are eyeglasses designed in such a way that different lenses can be inserted and can be used to correct refractive errors of vision. Ophthalmic trial frames are light weight, adjustable and should have a comfortable nose resting and can be adjusted to allow accurate centering.
Ophthalmic Eye Shield Market Segmentation By Material type Aluminium Ophthalmic …
Eye shields are advised for use in the eye while a periorbital surgery to avoid any injury to the globe. Ophthalmic eye shields are used for postoperative ocular protection. Ophthalmic eye shields protect the cornea and retina while any eye surgery or laser treatment. Ophthalmic eye shields are highly preferred for cataract surgeries in the elder population and blepharitis correction especially for children. According to WHO, The World Health Organization,
04-08-2019 | Health & Medicine
Fact.MR
Eye socket Implants Market Offered in New Research Forecasted through 2026 // Ke …
The global Eye socket Implants market is expected to see remarkable growth in the forecast period due to increase in work-related eye injuries. Increase in the number of patients drives the overall eye socket implants market. Higher adoption of surgeries in higher economic regions propels the Eye socket Implants Market. Others factors like increasing prevalence and incidence of eye-related disease, changing lifestyle pattern are the factors which are fueling the
Ophthalmic Surgical Technologies Market - Femtosecond Systems Likely to Dominate …
The global ophthalmic surgical technologies market is driven mainly by the growing funding in the healthcare sector and the rising awareness about eye care, added to the rising prevalence of eye diseases. The ophthalmic surgical technologies market has enjoyed a supportive regulatory and economic structure in most regions in the recent past and is thus likely to continue on the strong growth trajectory it has exhibited in recent years. Increasing
Ophthalmic Lasers Market: Demand for Ophthalmic Lasers to Remain Higher in North …
Lasers have become an essential part of treatment modality for a number of practicing ophthalmologist. Ophthalmic lasers have gained prominence with the popularity of laser-assisted surgeries for rectifying nearsightedness or myopia. The increasing incidence of ophthalmic disorders and rise in geriatric population in various regions have boosted the application of different types of lasers in treating specific eye problems and improving vision. Technological advances have significantly increased the safety and
Ophthalmic Ultrasound Device Market: A-scan Ophthalmic Ultrasound Devices High i …
Global Ophthalmic Ultrasound Device Market: Snapshot The constantly increasing percentage of the geriatric population across the world is widely considered as the primary factor augmenting the demand for ophthalmic ultrasound devices. The high geriatric population is directly linked to the increasing patient count for ocular diseases and disorders, along with chronic diseases such as diabetes. The increasing levels of pollution are also responsible for the high volume of ovular disorders across